Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by C.A. Burnett
A Phase 1/2 Study of Mt-3724 to Evaluate Safety, Pharmacodynamics and Efficacy of Mt-3724 for the Treatment of Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Related publications
Portia: A Phase 1b Study Evaluating Safety and Efficacy of Tisagenlecleucel and Pembrolizumab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Emerging Therapies for the Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma
Current Oncology
Oncology
Phase 2 Study of Parsaclisib (Incb050465) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (Dlbcl) (Citadel-202)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
A Phase Iia Study Evaluating the Safety and Tolerability of Umbralisib and Ibrutinib in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma
Annals of Hematology
Medicine
Hematology
Safety and Activity of Ibrutinib in Combination With Durvalumab in Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B‐cell Lymphoma
American Journal of Hematology
Hematology
Bianca: A Phase 2 Study of the Safety and Efficacy of Tisagenlecleucel in Pediatric Patients With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Pcn72 - Budget Impact Analysis of Tisagenlecleucel for the Treatment of Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in England
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase 2 Checkmate 436 Study
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
